Budesonide Inhaler Market To Surpass US$ 8.24 Billion By 2026 - Coherent Market Insights
Budesonide Inhaler Market Report Analyses competitive environment such as key players, future trends, growths, challenges and acquisitions in the market.
Key players in the market are focused on developing generics version of budesonide inhaler in affordable prices and in various forms such as dry powder, aerosols, suspensions or spray for asthma patients. Increasing number of regulatory approvals for generic versions of budesonide inhaler is a major factor driving growth of the budesonide inhaler market.
In September 2016, Orion Corporation announced that it has entered into a collaboration agreement with Menarini Group for the co-marketing of budesonide-formoterol Easyhaler combination product in Germany, Italy, Spain, and Portugal. Budesonide-formoterol Easyhaler is an inhaled combination product indicated for asthma and chronic obstructive pulmonary disease (COPD). In this formulation, budesonide acts as an anti-inflammatory agent and formoterol acts as a long-acting bronchodilator. The product is available under the brand name Bufomix Easyhaler in most of the European countries.
* The sample copy includes: Report Summary, Table of Contents, Segmentation, Competitive Landscape, Report Structure, Methodology.
Request a sample copy of this report: https://www.coherentmarketinsights.com/
Browse 21 Market Data Tables and 19 Figures spread through 149 Pages and in-depth TOC on "Global Budesonide Inhaler Market, by Product Type (Inhalants and Nebulizer), by Dosage (Aerosols, Dry Powder, Suspension, and Sprays), by Strength (0.25mg, 0.5mg, and 1.0mg), by Distribution Channel (Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy),
Browse Research Report: https://www.coherentmarketinsights.com/
Key Takeaways of the Budesonide Inhaler Market:
The global budesonide inhaler market is expected to witness a CAGR of 5.8% during the forecast period (2018–2026)
Among product type, the inhalant segment is expected to hold major revenue share in the market over the forecast period.
Key players in the market are focused on developing generic versions of budesonide inhaler for asthma and COPD, which is expected to drive growth of the inhalant segment in the market. For instance, in 2017, Cipla Ltd. received final approval for Budesonide Inhalation Suspension, from the U.S. FDA to market a generic version of AstraZeneca's Pulmicort Respules.
Buy-Now this research report: https://www.coherentmarketinsights.com/